
IPO · Windward Bio
Windward Bio prices $175M IPO and adds $50M from Sanofi to chase Tezspire
The Basel immunology company sold about 10.3 million shares at $17, and Sanofi is buying $50 million more in a side placement. Its lead drug targets TSLP, the same protein as AstraZeneca and Amgen's asthma drug Tezspire.



